null

VivoGenie Anti-Human GD2 (Naxitamab) Biosimilar (IVMB0413)

SKU:
IVMB0413
Antibody Type:
In Vivo Biosimilar
Endotoxin Level:
Low Endotoxin
Applications:
In Vivo
Disease Area:
Cancer
$407 - $13,535

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human GD2 (Naxitamab)
SKU:IVMB0413
Size:1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:hu3F8
Target:GD2
Isotype:Human IgG1κ
Host Species:Human
Reactivity:Human
Applications:in vivo
Expression Host:HEK-293 Cells
FC Effector Activity:Active
Synonyms:human ganglioside GD2, disialoganglioside
Product Concentration:≥ 5.0 mg/ml
Purity:≥95% by SDS Page
Immunogen:Human GD2
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Antigen Distribution:GD2 is a cell surface glycolipid present in low concentrations on skin, neural, or peripheral nerve cell surfaces. GD2 is overexpressed on neuroblastoma cells, most melanoma, and some other tumors.
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Naxitimab. Clone hu3F8 recognizes Human GD2. This product is for research use only.
Additional Applications Reported In Literature:ELISAFCFAWB
Recommended Isotype Controls:Human IgG1

Neuroblastoma is an extracranial childhood cancer that accounts for 12% of cancer deaths in children 1. Neuroblastomas highly express the antigen GD2, a glycolipid that assists in the attachment of tumor cells to the extracellular matrix 2.

Naxitamab (hu3F8) is a humanized IgG1 anti-GD2 monoclonal antibody developed for the treatment of neuroblastoma, osteosarcoma, and other GD2-positive cancers 3. Naxitamab was engineered by grafting the complementarity determining regions of murine 3F8 (m3F8) onto human IgG1 frameworks and optimizing the sequences for stability, binding kinetics to GD2, and efficiency in antibody dependent cell-mediated cytotoxicity (ADCC) 4. Naxitamab demonstrates direct cytotoxicity against neuroblastoma cell line LAN-1 in vitro and induces complement dependent cytotoxicity as well as ADCC 3,4. Naxitamab has low level cross-reactivity with the ganglioside GD1b and no cross-reactivity with human N-CAM 4.

The chemical name for naxitamab is immunoglobulin G1, anti-(ganglioside GD2) (humanized mus musculus clone hu3f8 gamma1-chain), disulfide with humanized mus musculus clone hu3f8 light-chain, dimer 3.

State of Matter:Liquid
Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Product Preparation:Recombinant biosimilar antibodies are manufactured in an animal free facility using onlyin vitroprotein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Research Area:Biosimilars

Related Products